Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 41, Issue 7, 1998, Pages 1258-1265

  Paleolog, Ewa M ^a   Young, Sylvia ^a   Stark, Alison C ^a   McCloskey, Richard V ^c   Feldmann, Marc ^b,c   Maini, Ravinder N ^b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; METHOTREXATE; RECOMBINANT INTERLEUKIN 1; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SYNOVIUM; VASCULAR ENDOTHELIUM;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CELL HYPOXIA; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIAL GROWTH FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LYMPHOKINES; METHOTREXATE; RECEPTORS, INTERLEUKIN-1; SIALOGLYCOPROTEINS; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031810231     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1     Document Type: Article

References (34)

1. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
3. Colville-Nash P, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51:919-25.
4. Thomas KA. Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem 1996;271:603-6.
5. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
6. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Yeo TK, Berse B, et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994;180:341-6.
7. Paleolog E. Angiogenesis: a critical process in the pathogenesis of RA - a role for VEGF? Br J Rheumatol 1996;35:917-20.
8. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
9. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
10. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smollen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
11. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNF α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7.
12. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996;39:1082-91.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Sustained therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. In press.
15. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995; 270:19761-6.
16. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia: modulation of gene expression by nitric oxide. J Clin Invest 1995;95:1798-807.
17. Damert A, Ikeda E, Risau W. Activator-protein-1 binding potentiates the hypoxia-inducible factor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem J 1997;327:419-23.
18. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. flt-1, but not flk-1/kdr, is up-regulated by hypoxia. J Biol Chem 1997;272:23659-67.
19. Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994;157:291-9.
20. Oliver SJ, Cheng TP, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell Immunol 1996;166:196-206.
21. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 1988;73:449-55.
22. Iijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int 1993;44:959-66.
23. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995;372:83-7.
24. Blake DR, Merry P, Unsworth J, Kidd BL, Outhwaite JM, Ballard R, et al. Hypoxic-reperfusion injury in the inflamed human joint. Lancet 1989-1:289-93.
25. Falchuk KH, Goetzl EJ, Kulka JP. Respiratory gases of synovial fluids: an approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis. Am J Med 1970;49:223-31.
26. Ferrara N. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36:127-37.
27. Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994;1221:211-4.
28. Soubrier M, Dubost J-J, Authier F-J, Serre AF, Ristori J-M, Sauvezie B, et al. Growth factors in POEMS syndrome: evidence for a marked increase of circulating vascular endothelial growth factor [abstract]. Arthritis Rheum 1996;39 Suppl 9:S131.
29. Watanabe O, Arimura K, Kitajima I, Osame M, Maruyama I. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet 1996;347:702.
30. Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, de Pooter C, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996;7:843-8.
31. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, de Pooter C, et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997;76:238-45.
32. Salven P, Maenpaa H, Orpana A, Alitalo A, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997;3:647-51.
33. Salven P, Teerenhovi L, Joensuu H. A high pre-treatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90:3167-72.
34. Kalden-Nemeth D, Grebmeier J, Antoni C, Manger B, Wolf F, Kalden JR. NMR monitoring of rheumatoid arthritis patients receiving anti-TNFα monoclonal antibody therapy. Rheumatol Int 1997;16:249-55.